The NCPE does not recommend the reimbursement of Pomalidomide for the treatment of Refractory or Relapsed and Refractory Multiple Myeloma at the submitted price.
Vacancy for a health technology assessor with the NCPE
The NCPE finds dimethyl fumarate (Tecfidera®) not cost-effective for the treatment of adult patients with relapsing remitting MS and therefore does not recommend reimbursement at the submitted price
The NCPE Review Group concludes that, at the current price, pregabalin (Lyrica®) is not cost effective as a first line treatment for generalised anxiety disorder.
The NCPE does not recommend reimbursement of radium-223 at the submitted price.
The NCPE recommends reimbursement of Sovaldi® for certain subgroups.
The NCPE do not recommend reimbursement of nab-paclitaxel (Abraxane®).
The NCPE does not recommend reimbursement under the submitted pricing structure.
The NCPE does not recommend reimbursement of lixisenatide for patients with type 2 diabetes mellitus at the submitted price.
The NCPE recommends reimbursement of alemtuzumab (Lemtrada®).